Why Medication Reviews Matter More as People Age

AARP’s latest consumer guide highlights how prescription drugs, over-the-counter products and supplements can become harder to manage with age—and why regular medication reviews can help catch problems early.
FDA Adds Rare Eye-Risk Warning to GLP-1 Medicines

The FDA is requiring warning-label updates for GLP-1 drugs after reviewing data on a rare eye condition that can cause sudden, permanent vision loss.
Testosterone Therapy and Heart Safety: What Women Should Know

New research presented at a menopause conference raises fresh questions about cardiovascular safety in women using testosterone therapy, which is not FDA-approved for women.
What consumers should know about unregulated peptide products

A Washington Post report highlights people who say they felt worse after using experimental peptides, while FDA warnings underline that many of these products have not been proven safe or effective.
Long-Term Care Medication Risks That Deserve a Second Look

AARP’s latest caregiving guidance highlights why medication lists in long-term care need regular review—especially for drugs linked to confusion, falls, and other side effects.